Table 1 Comparisons of cycle characteristics in the agonist and the antagonist groups.

No. of cycles

331

203

ICSI rate

42% (139/331)

43% (87/203)

NS

Age of patients

33.9 ± 0.2 (22–45)

34.4 ± 0.3 (26–46)

NS

Duration of stimulation (days)

11.3 ± 0.1

9.9 ± 0.1

< 0.05

No. of ampoules used per cycle

38.6 ± 0.5

35.4 ± 0.4

NS

Peak E₂ level

2347.8 ± 71.9

1731.5 ± 81.1

< 0.0001

No. of oocytes retrieved per cycle

10.0 ± 0.3

8.2 ± 0.4

< 0.05

No. of mature oocytes per cycle

9.0 ± 0.3

7.2 ± 0.3

< 0.05

No. of normal fertilized oocytes per cycle

6.1 ± 0.3 (2019)

5.7 ± 0.3 (1157)

NS

Total no. of embryos

2259

1166

Good embryo rate

IVF

54.6% (715/1309)^a

56.5%(375/664)^c

ICSI

54.4% (517/950)^b

56% (281/502)^d

No. of embryo transfer

3.8 ± 0.1

3.32 ± 0.9

NS

Embryonic early cleavage rate

IVF

34% (450/1309)

20% (133/664)

< 0.0001

ICSI

50% (476/950)

37.8% (190/502)

< 0.0001

Pregnancy rate (%)

IVF

46.9% (90/192)

44.8% (52/116)

NS

ICSI

46.8% (65/139)

44.8% (39/87)

NS

Implantation rate

IVF

21.9% (160/730)

19% (73/384)

NS

ICSI

21.2% (112/528)

18.9% (55/290)

NS

On going pregnancy rate

IVF

35.9% (69/192)

38.8% (45/116)

NS

ICSI

36% (50/139)

39% (34/87)

NS